Skip to main content
Feedback to SSRN
Feedback
(required)
Email
(required)
Submit
Judith M. Versluis
affiliation not provided to SSRN
Contact
affiliation not provided to SSRN
Email
Learn more about SSRN Profiles
SCHOLARLY PAPERS
1
DOWNLOADS
44
TOTAL CITATIONS
0
Feedback
Scholarly Papers (1)
Sort by:
Paper Title, A-Z
Paper Title, Z-A
Author Name, A-Z
Author Name, Z-A
Date Posted, Ascending
Date Posted, Descending
Downloads, Ascending
Downloads, Descending
Citations, Ascending
Citations, Descending
Actions:
Email selected abstracts
View:
Selected
Original List
All Versions
Hide All Versions
All Abstracts
Hide All Abstracts
(Rank)
1.
Real-World Outcomes with Ipilimumab and Nivolumab in Advanced Melanoma: A Multicentre Retrospective Study
Number of pages: 20
Posted: 31 Mar 2022
Patricio Serra-Bellver
, Judith M. Versluis,
Honey K. Oberoi
,
Cong Zhou
,
Timothy D. Slattery
,
Yasir Khan
,
James R. Patrinely
,
Ines Pires da Silva
,
Clara Martinez-Vila
,
Natalie Cook
,
Donna Graham
,
Matteo Carlino
,
Alexander M. Menzies
,
Ana M. Arance
,
Douglas B. Douglas
,
Georgina V. Long
,
Lisa Pickering
,
James M. G. Larkin
,
Christian U. Blank
and
Paul Lorigan
Manchester Academic Health Sciences Centre - The Christie NHS Foundation Trust,
affiliation not provided to SSRN
,
affiliation not provided to SSRN
,
affiliation not provided to SSRN
,
affiliation not provided to SSRN
,
affiliation not provided to SSRN
,
affiliation not provided to SSRN
, The University of Sydney - Melanoma Institute Australia,
affiliation not provided to SSRN
, The University of Manchester, The Christie NHS Foundation Trust, Blacktown Hospital, The University of Sydney - Melanoma Institute Australia, Hospital of Barcelona, Vanderbilt University - Vanderbilt-Ingram Cancer Center, The University of Sydney - Melanoma Institute Australia, Royal Marsden NHS Foundation Trust - Renal and Skin Units, NHS Foundation Trust - Royal Marsden Hospital, Netherlands Cancer Institute and The University of Manchester
Downloads
44
(1,145,425)
View PDF
Download
Abstract:
melanoma, real-world, ipilimumab+nivolumab, immunotherapy
Feedback